A single center open label phase 2 randomised control trial (Clinical Trial Registry of India
No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of …

Introduction A single center open label phase II randomised control trial was done to assess
the pathogen and host-intrinsic factors influencing clinical and immunological benefits of …

Importance Convalescent plasma is a potential therapeutic option for patients with
coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are …

Abstract Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …

Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Background Convalescent plasma is frequently administered to patients with Covid-19 and
has been reported, largely on the basis of observational data, to improve clinical outcomes …

Background Convalescent plasma (CP), despite limited evidence on its efficacy, is being
widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed …

Background The role of convalescent plasma therapy for patients with coronavirus disease
2019 (COVID‐19) is unclear. Methods We retrospectively compared outcomes in a cohort of …

Abstract Introduction South America is one of the regions most affected by the COVID‐19
pandemic. Specific and affordable treatments are needed to treat SARS‐CoV‐2 infection …